Vancouver, British Columbia–(Newsfile Corp. – April 17, 2024) – Defense Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“defense” or “companyA Canadian biopharmaceutical company developing new immuno-oncology therapies and drug delivery technologies has been commissioned by the Department of Defense to execute its financing strategy, with European corporate finance consulting firm FMS Consult GmbH (“FMS”). I announced something. company.
“Defense’s successful technology development has enabled us to grow into a clinical-stage oncology company. To fuel our growth, Defense has a strong European-based financial team with extensive biotechnology experience. We have secured an advisor for Accum, Defense's lead technology.® The platform has proven to be a broad and effective cancer-killing technology for multiple indications and applications, including ADCs, cancer vaccines, and anti-cancer injectables,” said Defense CEO and President. says Plouffe.
Regarding defense:
Defense Therapeutics is a publicly traded clinical-stage biotechnology company using its proprietary platform to develop next-generation vaccines and ADC products. At the core of the Defense Therapeutics platform is ACCUM® This technology allows for precise delivery of intact vaccine antigens or ADCs to target cells. The result is increased effectiveness and potency against devastating diseases such as cancer and infectious diseases.
For more information:
Sebastian Plouffe, President, CEO, Director
Phone: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Notes regarding “forward-looking” information
This release contains certain statements that may be considered “forward-looking statements.” All statements, other than statements of historical fact, in this release about events or developments that the Company expects to occur are forward-looking statements. Forward-looking statements are statements that are not historical facts and generally include, but are not limited to, the words “expect,” “plan,” “anticipate,” “believe,” “intend,” and “estimate.” , identified by the word “to plan.” , “potential” and similar expressions, or that an event or condition “will”, “will”, “may”, “could”, or “should” occur. thing. Although the Company believes that the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ from those in the forward-looking statements. The content may differ significantly. Factors that could cause actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, the continued availability of capital and financing, and general economic, market, or business situations. Investors are cautioned that such statements are not guarantees of future performance and actual results or developments may differ materially from those anticipated in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates, opinions or other factors change. not.
Neither the CSE nor its market regulator accepts responsibility for the adequacy or accuracy of this release as that term is defined in the policies of the CSE.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/205733.
